Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data
Pictured (from left): Pfizer and Alnylam signs/Taylor Tieden for BioSpace Unveiled late last month, topline results from a Phase III trial of Alnylam’s RNAi therapy Amvuttra in ATTR amyloidosis with cardiomyopathy are turning some heads. The treatment …